NASDAQ:KOD Kodiak Sciences Q3 2026 Earnings Date & Estimates $88.12 +7.03 (+8.67%) Closing price 04:00 PM EasternExtended Trading$88.25 +0.13 (+0.15%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kodiak Sciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Kodiak Sciences in Q3 2026Kodiak Sciences is expected to post earnings of -$1.06 per share. In the same quarter a year earlier Kodiak Sciences reported -$1.16 per share. Kodiak Sciences last reported on August 13, 2026, posting -$1.05 per share and missing the -$0.9565 consensus estimate. Kodiak Sciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.06Prior-Year EPS-$1.16Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.05 (Missed by -$0.0935)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Kodiak Sciences Q3 2026 Earnings FAQ When does Kodiak Sciences report Q3 2026 earnings? Kodiak Sciences (NASDAQ:KOD) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Kodiak Sciences' Q3 2026 earnings call? Kodiak Sciences' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Kodiak Sciences? Analysts expect Kodiak Sciences to post earnings of -$1.06 per share for Q3 2026. Kodiak Sciences Earnings HeadlinesHC Wainwright Comments on Kodiak Sciences FY2030 EarningsOctober 15 at 2:44 AM | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)October 13 at 12:14 PM | theglobeandmail.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.October 15 at 1:00 AM | Profits Run (Ad)Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - SlideshowOctober 10, 2026 | seekingalpha.comKodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial NewsOctober 9, 2026 | finance.yahoo.comKodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data UpdateOctober 8, 2026 | finance.yahoo.comSee More Kodiak Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email. Email Address About Kodiak SciencesKodiak Sciences (NASDAQ:KOD) (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye. Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Its principal investigational product, KSI-301, is an anti-VEGF-A therapy designed for longer-lasting activity than conventional treatments. Kodiak has also researched KSI-501, a potential dual-action therapy intended to target both VEGF-A and inflammatory pathways implicated in retinal disease. Founded in 2009, Kodiak has conducted clinical development activities in the United States and other international markets. The company is led by Victor Perlroth, M.D., who co-founded Kodiak and has served as its chief executive officer. Kodiak’s development programs remain focused on addressing the treatment burden associated with frequent intraocular injections for patients with retinal disorders.View Kodiak Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
